AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs for hypertension, breast cancer and generalized myasthenia gravis, all of which are currently under FDA review.
JPM26: AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Launches